Tag:
Matthew Emmens
Latest Headlines
Latest Headlines
Vertex chief earned $13.4M in '11
Former Vertex CEO Matthew Emmens left the company after reaping $13.4 million in total compensation last year, according to the Boston Business Journal .
Vertex chief's pay dropped to $13.4M last year
Outgoing Vertex Pharmaceuticals CEO Matthew Emmens saw his 2011 compensation drop slightly, despite the company's successful launch of its new hepatitis C drug, Incivek.
Interview: Vertex CEO worries about 'hyper-focus' on hep C
No question that Vertex Pharmaceuticals ( $VRTX ) needs another hit to follow its new hepatitis C drug Incivek. But that's just one of the things on the to-do list for incoming CEO Jeffrey Leiden, who
Interview: Vertex CEO concerned about investors' 'hyper-focus' on hep C
Matthew Emmens
On the heels of Vertex Pharmaceuticals' ( $VRTX ) big news last week about changing CEOs next year, FierceBiotech chatted with both current chief executive Matt Emmens
Vertex's new leader expected to diversify
Vertex Pharmaceuticals ( $VRTX ) will be getting its second new leader in two years as it seeks to become a more diversified drug company. Former Abbott Laboratories executive Jeffrey Leiden will
Vertex CEO stepping down after banner year
Apparently, Matthew Emmens wanted to announce his departure from his CEO post at Vertex Pharmaceuticals ( $VRTX ) at what could be considered the pinnacle of his tenure at the company. Emmens, who was
The vote for best biotech CEO goes to…
Who's the best CEO in biotech? TheStreet posed that question to its readers and came up with Matthew Emmens , who helms Vertex ( $VRTX ). Vertex has had a big year, of course, with the successful launch
Vertex CEO takes Morgan Stanley analyst to task at conference
Vertex Pharmaceuticals ( $VRTX ) CEO Matthew Emmens didn't stick with the script at yesterday's Morgan Stanley Global Healthcare Conference. Armed with stellar early sales figures for Vertex's new hep
Vertex CEO Emmens offers analyst a barbed review of his own
Anyone who's been to one of the big investment banking biotech conferences knows the routine. The CEO makes a few well considered, practiced remarks and carefully stays on script. But Vertex ( $VRTX )
Battling bullies and other tales by Vertex's new CEO
Matthew Emmens hates golf. For more on the new CEO of Vertex Pharmaceuticals--and ex-chief of Shire--see the Boston Business Journal profile. One tidbit: He's written an allegorical business tale
